Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?

Pharmacol Res. 2020 Jun:156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.

¹ ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy.
² Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Guraiger, Abha, 62529, Saudi Arabia.
³ ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy; Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. Electronic address: A.J.Iqbal@bham.ac.uk.
⁴ ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy. Electronic address: francesco.maione@unina.it.

No abstract available

Publication types